Over the next few months, well be focusing on: Educating providers on optimizing GLP-1 outcomes Sharing patient success strategies Highlighting the clinical role of dietitians in medical weight management Providing actionable tools to support your patients Our goal is simple: Bridge the gap between medication and meaningful, lasting results
According to NICE guidance (NG28), GLP-1 receptor agonists like Ozempic are typically considered for people with type 2 diabetes who have inadequate glycaemic control despite treatment with metformin and other oral medications, or when other treatment options are contraindicated or not tolerated
Heres how the numbers compare: This approach isnt entirely new to medicine
Lower doses appear to carry substantially less risk
Protein shakes formulated for GLP-1 users are the most practical solution
Without the right expertise, companies often end up with brittle integrations, unreliable infrastructure, and compliance gaps that become costly to fix later